{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:18:59Z","timestamp":1768468739550,"version":"3.49.0"},"reference-count":84,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T00:00:00Z","timestamp":1471910400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>There have been major recent advancements in the understanding and management of multiple myeloma. Diagnostic criteria have been revised and former ultra-high-risk smoldering multiple myeloma is now considered multiple myeloma in need of treatment. Understanding clonal progression, evolution, and tides not only has helped elucidate the disease behavior but might help expand therapeutic choices in order to select appropriate treatment for patients. Unprecedented response rates with modern triplet induction therapies containing proteasome inhibitor and immunomodulators have made this approach standard for initial treatment. The US Food and Drug Administration approved four new drugs (two targeted antibodies and two oral agents) in 2015 in relapsed\/refractory multiple myeloma and these drugs along with the other already-available drugs have now increased the choices of regimens. Even drugs without single-agent activity, such as panobinostat and elotuzumab, have an important role, especially in the proteasome inhibitor refractory setting. Recent studies done in the context of novel agent induction suggest that high-dose therapy followed by autologous transplant continues to improve response rates and progression-free survival, thus underscoring their role in transplant-eligible patients. Evolving paradigms in the treatment of multiple myeloma include newer promising immune approaches, such as adoptive cellular therapies, vaccines, or antibody-based immune manipulations. Though multiple myeloma is still considered incurable, it is clear that with the improved understanding of disease biology and clonal architecture of relapse combined with the availability of multi-targeted approaches, we are ever closer to a lasting cure or transformation into indolent and long-lasting disease courses or both.<\/ns4:p>","DOI":"10.12688\/f1000research.8777.1","type":"journal-article","created":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T15:15:07Z","timestamp":1471965307000},"page":"2053","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Recent advances in understanding multiple myeloma"],"prefix":"10.12688","volume":"5","author":[{"given":"Binod","family":"Dhakal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saulius","family":"Girnius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parameswaran","family":"Hari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2016,8,23]]},"reference":[{"key":"ref-1","article-title":"SEER Cancer Statistics Review (CSR) 1975\u20132013","author":"N Howlader","year":"2016"},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"e538-48","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.","volume":"15","author":"S Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"3069-75","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma.","volume":"125","author":"S Rajkumar","year":"2015","journal-title":"Blood."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"1738-44","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.","volume":"27","author":"S Rajkumar","year":"2013","journal-title":"Leukemia."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"4325-32","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.","volume":"31","author":"K Neben","year":"2013","journal-title":"J Clin Oncol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"2582-90","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.","volume":"356","author":"R Kyle","year":"2007","journal-title":"N Engl J Med."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"1606-10","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.","volume":"28","author":"J Hillengass","year":"2010","journal-title":"J Clin Oncol."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"785-9","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.","volume":"111","author":"A Dispenzieri","year":"2008","journal-title":"Blood."},{"key":"ref-9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.123","article-title":"Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.","author":"V Gonz\u00e1lez-Calle","year":"2016","journal-title":"Leukemia."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"438-47","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.","volume":"369","author":"M Mateos","year":"2013","journal-title":"N Engl J Med."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"746-54","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.","volume":"1","author":"N Korde","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"2863-9","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.","volume":"33","author":"A Palumbo","year":"2015","journal-title":"J Clin Oncol."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"335-48","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma.","volume":"12","author":"G Morgan","year":"2012","journal-title":"Nat Rev Cancer."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"3049-58","DOI":"10.1182\/blood-2014-11-568881","article-title":"Pathogenesis beyond the cancer clone(s) in multiple myeloma.","volume":"125","author":"G Bianchi","year":"2015","journal-title":"Blood."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"3911-20","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.","volume":"33","author":"B Walker","year":"2015","journal-title":"J Clin Oncol."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.","volume":"5","author":"N Bolli","year":"2014","journal-title":"Nat Commun."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"1067-76","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma.","volume":"120","author":"J Keats","year":"2012","journal-title":"Blood."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"142-52","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.","volume":"372","author":"A Stewart","year":"2015","journal-title":"N Engl J Med."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"25-32","DOI":"10.1111\/ejh.12677","article-title":"\u2018Real-life\u2019 experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.","volume":"97","author":"S Danhof","year":"2016","journal-title":"Eur J Haematol."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"899-906","DOI":"10.1182\/blood-2014-02-556308","article-title":"A phase 2 single-center study of carfilzomib 56 mg\/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.","volume":"124","author":"N Lendvai","year":"2014","journal-title":"Blood."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"1970-80","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.","volume":"70","author":"E Kupperman","year":"2010","journal-title":"Cancer Res."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1038\/bcj.2015.60","article-title":"Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib.","volume":"5","author":"S Kumar","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"1621-34","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.","volume":"374","author":"P Moreau","year":"2016","journal-title":"N Engl J Med."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"305-9","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.","volume":"343","author":"G Lu","year":"2014","journal-title":"Science."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"301-5","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.","volume":"343","author":"J Kr\u00f6nke","year":"2014","journal-title":"Science."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"1055-66","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.","volume":"14","author":"J San Miguel","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"1411-7","DOI":"10.1182\/blood-2014-11-612069","article-title":"Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and\/or translocation (4;14): IFM 2010-02 trial results.","volume":"125","author":"X Leleu","year":"2015","journal-title":"Blood."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"820-3","DOI":"10.1111\/bjh.13227","article-title":"Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone.","volume":"168","author":"G Morgan","year":"2015","journal-title":"Br J Haematol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"902-7","DOI":"10.1093\/annonc\/mdw017","article-title":"Safe and prolonged survival with long-term exposure to pomalidomide in relapsed\/refractory myeloma.","volume":"27","author":"G Fouquet","year":"2016","journal-title":"Ann Oncol."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"1573-85","DOI":"10.1038\/leu.2014.60","article-title":"Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.","volume":"28","author":"M Dimopoulos","year":"2014","journal-title":"Leukemia."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"351-8","DOI":"10.1111\/bjh.12152","article-title":"Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.","volume":"160","author":"R Rosovsky","year":"2013","journal-title":"Br J Haematol."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"2331-7","DOI":"10.1182\/blood-2013-01-481325","article-title":"PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.","volume":"122","author":"P Richardson","year":"2013","journal-title":"Blood."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"1195-206","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.","volume":"15","author":"J San-Miguel","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"1207-19","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.","volume":"373","author":"H Lokhorst","year":"2015","journal-title":"N Engl J Med."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"621-31","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.","volume":"373","author":"S Lonial","year":"2015","journal-title":"N Engl J Med."},{"key":"ref-36","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood.V126.23.509.509","article-title":"A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAB) As a Single Agent in Relapsed\/Refractory Multiple Myeloma.","volume":"126","author":"T Martin","year":"2015","journal-title":"Blood."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"2075-85","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.","volume":"376","author":"M Cavo","year":"2010","journal-title":"Lancet."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"5752-8; quiz 5982","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.","volume":"118","author":"P Moreau","year":"2011","journal-title":"Blood."},{"key":"ref-39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood.V126.23.25.25","article-title":"Bortezomib, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777.","volume":"126","author":"B Durie","year":"2015","journal-title":"Blood."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"1337-41","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.","volume":"23","author":"C Reeder","year":"2009","journal-title":"Leukemia."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"2569-74","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.","volume":"127","author":"P Moreau","year":"2016","journal-title":"Blood."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"1801-9","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.","volume":"120","author":"A Jakubowiak","year":"2012","journal-title":"Blood."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"1102-8","DOI":"10.1182\/blood-2015-08-662627","article-title":"Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.","volume":"127","author":"V Magarotto","year":"2016","journal-title":"Blood."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"2068-74","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.","volume":"125","author":"A Palumbo","year":"2015","journal-title":"Blood."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1038\/bcj.2011.34","article-title":"Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score.","volume":"1","author":"M Kleber","year":"2011","journal-title":"Blood Cancer J."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"2475-82","DOI":"10.1200\/JCO.2011.37.4918","article-title":"Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR\/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.","volume":"30","author":"L Garderet","year":"2012","journal-title":"J Clin Oncol."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"91-7","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome.","volume":"335","author":"M Attal","year":"1996","journal-title":"N Engl J Med."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"1875-83","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.","volume":"348","author":"J Child","year":"2003","journal-title":"N Engl J Med."},{"key":"ref-49","doi-asserted-by":"crossref","first-page":"3131-6","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.","volume":"92","author":"J Fermand","year":"1998","journal-title":"Blood."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"4647-54","DOI":"10.1182\/blood-2012-11-464503","article-title":"Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.","volume":"121","author":"U Mellqvist","year":"2013","journal-title":"Blood."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"1116-23","DOI":"10.1016\/j.bbmt.2013.04.027","article-title":"Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995\u20132005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age.","volume":"19","author":"P McCarthy","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"9-19","DOI":"10.1200\/JCO.2009.23.7172","article-title":"Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.","volume":"120","author":"M Cavo","year":"2012","journal-title":"Blood."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"2077-84","DOI":"10.1200\/JCO.2009.23.7172","article-title":"Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.","volume":"28","author":"M Ladetto","year":"2010","journal-title":"J Clin Oncol."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"4017-23","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.","volume":"112","author":"B Paiva","year":"2008","journal-title":"Blood."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"1617-29","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.","volume":"16","author":"F Gay","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"895-905","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma.","volume":"371","author":"A Palumbo","year":"2014","journal-title":"N Engl J Med."},{"key":"ref-57","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood.V126.23.391.391","article-title":"Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM\/DFCI 2009 Trial).","volume":"126","author":"M Attal","year":"2015","journal-title":"Blood."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"1770-81","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma.","volume":"366","author":"P McCarthy","year":"2012","journal-title":"N Engl J Med."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"1782-91","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.","volume":"366","author":"M Attal","year":"2012","journal-title":"N Engl J Med."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"1589-96","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study.","volume":"120","author":"L Rosi\u00f1ol","year":"2012","journal-title":"Blood."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"2712-7","DOI":"10.1200\/JCO.2013.54.8164","article-title":"Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du My\u00e9lome.","volume":"32","author":"M Roussel","year":"2014","journal-title":"J Clin Oncol."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"3459-66","DOI":"10.1200\/JCO.2014.60.2466","article-title":"Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.","volume":"33","author":"A Palumbo","year":"2015","journal-title":"J Clin Oncol."},{"key":"ref-63","doi-asserted-by":"crossref","first-page":"1196-8","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle.","volume":"87","author":"G Tricot","year":"1996","journal-title":"Blood."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"1195-203","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.","volume":"12","author":"A Krishnan","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"5055-63","DOI":"10.1182\/blood-2012-11-69452","article-title":"Autologous\/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.","volume":"121","author":"G Gahrton","year":"2013","journal-title":"Blood."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"6721-7","DOI":"10.1182\/blood-2011-03-339945","article-title":"Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma.","volume":"117","author":"L Giaccone","year":"2011","journal-title":"Blood."},{"key":"ref-67","doi-asserted-by":"publisher","first-page":"3016-22","DOI":"10.1200\/JCO.2010.32.7312","article-title":"Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.","volume":"29","author":"B Bj\u00f6rkstrand","year":"2011","journal-title":"J Clin Oncol."},{"key":"ref-68","doi-asserted-by":"publisher","first-page":"3375-82","DOI":"10.1182\/blood-2008-07-167379","article-title":"Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo.","volume":"113","author":"B Bruno","year":"2009","journal-title":"Blood."},{"key":"ref-69","doi-asserted-by":"crossref","first-page":"3031-7","DOI":"10.1200\/JCO.2000.18.16.3031","article-title":"Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome.","volume":"18","author":"H Lokhorst","year":"2000","journal-title":"J Clin Oncol."},{"key":"ref-70","doi-asserted-by":"publisher","first-page":"288ra78","DOI":"10.1126\/scitranslmed.aaa7014","article-title":"Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma.","volume":"7","author":"K Noonan","year":"2015","journal-title":"Sci Transl Med."},{"key":"ref-71","doi-asserted-by":"publisher","first-page":"409-18","DOI":"10.1097\/CJI.0b013e31821ca6ce","article-title":"PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine.","volume":"34","author":"J Rosenblatt","year":"2011","journal-title":"J Immunother."},{"key":"ref-72","first-page":"37-46","article-title":"Immunotherapy with chimeric antigen receptors for multiple myeloma.","volume":"17","author":"A Garfall","year":"2014","journal-title":"Discov Med."},{"key":"ref-73","doi-asserted-by":"publisher","first-page":"393-402","DOI":"10.1182\/blood-2010-04-277137","article-title":"Vaccination with dendritic cell\/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.","volume":"117","author":"J Rosenblatt","year":"2011","journal-title":"Blood."},{"key":"ref-74","doi-asserted-by":"publisher","first-page":"788-97","DOI":"10.1182\/blood-2010-08-299396","article-title":"Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.","volume":"117","author":"A Rapoport","year":"2011","journal-title":"Blood."},{"key":"ref-75","doi-asserted-by":"publisher","first-page":"799-802","DOI":"10.1002\/ajh.21560","article-title":"Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival.","volume":"84","author":"M Lacy","year":"2009","journal-title":"Am J Hematol."},{"key":"ref-76","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1056\/NEJMc1512760","article-title":"Chimeric Antigen Receptor T Cells in Myeloma.","volume":"374","author":"A Garfall","year":"2016","journal-title":"N Engl J Med."},{"key":"ref-77","doi-asserted-by":"publisher","first-page":"2286-94","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.","volume":"116","author":"D Benson","year":"2010","journal-title":"Blood."},{"key":"ref-78","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood.V124.21.291.291","article-title":"Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies.","volume":"124","author":"A Lekoshin","year":"2014","journal-title":"Blood."},{"key":"ref-79","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1182\/blood.V126.23.505.505","article-title":"Pembrolizumab in combination with Lenalidomide and low-dose dexamethasone for Relapsed\/Refractory Multiple Myeloma (RRMM): Keynote-023.","volume":"126","author":"J San Miguel","year":"2015","journal-title":"Blood."},{"key":"ref-80","doi-asserted-by":"publisher","first-page":"4324-33","DOI":"10.1182\/blood-2012-06-438028","article-title":"A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed\/refractory multiple myeloma.","volume":"120","author":"D Benson","year":"2012","journal-title":"Blood."},{"key":"ref-81","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood.V126.23.929.929","article-title":"Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study.","volume":"126","author":"N Shah","year":"2015","journal-title":"Blood."},{"key":"ref-82","doi-asserted-by":"publisher","first-page":"24-36","DOI":"10.1097\/CJI.0000000000000059","article-title":"Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.","volume":"38","author":"S Szmania","year":"2015","journal-title":"J Immunother."},{"key":"ref-83","doi-asserted-by":"publisher","first-page":"579-85","DOI":"10.1182\/blood.V98.3.579","article-title":"Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.","volume":"98","author":"L Porrata","year":"2001","journal-title":"Blood."},{"key":"ref-84","doi-asserted-by":"publisher","first-page":"3043-51","DOI":"10.1182\/blood-2014-07-552059","article-title":"Curing myeloma at last: defining criteria and providing the evidence.","volume":"124","author":"B Barlogie","year":"2014","journal-title":"Blood."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/5-2053\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-2053\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-2053\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T12:51:35Z","timestamp":1601038295000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/5-2053\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,23]]},"references-count":84,"URL":"https:\/\/doi.org\/10.12688\/f1000research.8777.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.9446.r15771","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.9446.r15770","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.9446.r15769","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.9446.r15772","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,23]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/5-2053\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.9446.r15770, Monika Engelhardt, Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany, 23 Aug 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-2053\/v1#referee-response-15770","order":0,"name":"referee-response-15770","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.9446.r15772, Stefan Knop, Wilhelm Sander Myeloma Unit, Division of Hematology and Medical Oncology, Wuerzburg University Medical Center, Wuerzburg, Germany, 23 Aug 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-2053\/v1#referee-response-15772","order":1,"name":"referee-response-15772","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.9446.r15769, Qaiser Bashir, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, 23 Aug 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-2053\/v1#referee-response-15769","order":2,"name":"referee-response-15769","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.9446.r15771, David Avigan, Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, Massachusetts, USA, 23 Aug 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-2053\/v1#referee-response-15771","order":3,"name":"referee-response-15771","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":4,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}